<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS135919</article-id><article-id pub-id-type="doi">10.1101/2021.09.26.461873</article-id><article-id pub-id-type="archive">PPR400402</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="europepmc-category"><subject>Covid-19</subject></subj-group></article-categories><title-group><article-title>SARS- CoV-2 viroporins: A multi-omics insight from nucleotides to amino acids</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sarkar</surname><given-names>Manish</given-names></name><degrees>M.Sc.</degrees><xref ref-type="aff" rid="A1">1</xref><email>manish@medinsights.fr</email></contrib><contrib contrib-type="author"><name><surname>Etheimer</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="A2">2</xref><email>paul.etheimer@protonmail.com</email></contrib><contrib contrib-type="author"><name><surname>Hannothiaux</surname><given-names>Victor</given-names></name><degrees>M.Sc.</degrees><xref ref-type="aff" rid="A1">1</xref><email>victor.hannothiaux@medinsights.fr</email></contrib><contrib contrib-type="author"><name><surname>Saha</surname><given-names>Soham</given-names></name><degrees>Ph.D.</degrees><xref ref-type="aff" rid="A1">1</xref><email>soham@medinsights.fr</email></contrib></contrib-group><aff id="A1"><label>1</label>MedInsights, 6 rue de l’église, 02810 Veuilly la Poterie, France</aff><aff id="A2"><label>2</label>Université de Paris, 85 boulevard Saint-Germain, 75006 Paris, France</aff><pub-date pub-type="nihms-submitted"><day>29</day><month>09</month><year>2021</year></pub-date><pub-date pub-type="preprint"><day>26</day><month>09</month><year>2021</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://europepmc.org/downloads/openaccess</ali:license_ref><license-p>This preprint is made available via the <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/downloads/openaccess">Europe PMC open access subset</ext-link>, for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original preprint source.</license-p></license></permissions><abstract><p id="P1">COVID-19 is caused by SARS-CoV-2 which has so far affected more than 500 million people worldwide and killed over 6 million as of 1st May, 2022. The approved emergency-use vaccines were lifesaving to such a devastating pandemic. Viroporins are important players of the life cycle of SARS-CoV-2 and are primary to its pathogenesis. We studied the two prominent viroporins of SARS-CoV-2 (i) Orf3a and (ii) Envelope (E) protein from a sequential and structural point of view. Orf3a is a cation selective viral ion channel which has been shown to disrupt the endosomal pathways. E protein is one of the most conserved proteins among the SARS-CoV proteome which affects the ERGIC related pathways. The aqueous medium through the viroporins mediates the non-selective translocation of cations, affecting ionic homeostasis in the host cellular compartments. This ionic imbalance could potentially lead to increased inflammatory response in the host cell. Our results shed light into the mechanism of viroporin action, which can be potentially leveraged for the development of antiviral therapeutics. Our results corroborate with previously published transcriptomic data from COVID-19 infected lung alveolar cells where inflammatory responses and molecular regulators directly impacted by ion channelling were upregulated.</p></abstract><kwd-group><kwd>Orf3a</kwd><kwd>envelope protein</kwd><kwd>molecular dynamics</kwd><kwd>viroporin</kwd><kwd>ion channelling activity</kwd><kwd>transcriptomics</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><label>1</label><title>Introduction</title><p id="P2">The COVID-19 (CoronaVIrus Disease 2019) is a severe acute respiratory syndrome (SARS) caused by a novel pathogenic β-coronaviral strain, SARS-CoV-2 which has affected millions all over the world. Vaccines have been developed using various technologies which have been approved by FDA like ChAdOx1 nCoV- 19 (AstraZeneca) (<xref ref-type="bibr" rid="R1">1</xref>), mRNA-1273 (Moderna) (<xref ref-type="bibr" rid="R2">2</xref>), BNT162b2 (Pfizer) (<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4">4</xref>), Janssen Ad26.COV2.S (Janssen–Cilag International NV) (<xref ref-type="bibr" rid="R5">5</xref>), inactivated Vaccines (Vero Cell) (Sinopharm &amp; Sinovac Life Sciences) (<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R7">7</xref>) along with several other lead candidates in line. These vaccines are either whole inactivated viruses or have overlapping targets and origin which have been quite effective in mitigating the pandemic. SARS-CoV-2 has a genome encoding 28 proteins which play important roles in different stages of viral pathogenesis (<xref ref-type="bibr" rid="R8">8</xref>–<xref ref-type="bibr" rid="R11">11</xref>). The mRNA (Pfizer, Moderna), adenoviral vector-based (Astrazeneca, Janssen) and inactivated (Sinovac, Sinopharm) vaccines use epitopes from the spike protein to generate an immunogenic response in the body, thus creating an immunogenic memory. But since spike protein is very much prone to acquiring new mutations (<xref ref-type="bibr" rid="R12">12</xref>–<xref ref-type="bibr" rid="R14">14</xref>), these vaccines could lose their efficacies with the evolving viral genome (Center for Disease Control and Prevention). Emergence of numerous variants along with their sub-lineages of SARS-CoV-2 has been observed and is continuously being monitored (GISAID, W.H.O.). All of these variants have heavy mutational load on the spike protein (<xref ref-type="bibr" rid="R15">15</xref>–<xref ref-type="bibr" rid="R17">17</xref>), followed by the nucleocapsid (N) protein (<xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R19">19</xref>) and the RdRp (<xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R20">20</xref>–<xref ref-type="bibr" rid="R22">22</xref>). As a result, the cellular events involved in the viral pathogenesis, which are more conserved phylogenetically, become important. Ion channelling activity is one such feature which encompasses viroporins. These viroporins’ counter balance host cellular responses range from opposite directional ion flow to downstream disruptions of the host cell signalling pathways (<xref ref-type="bibr" rid="R23">23</xref>–<xref ref-type="bibr" rid="R25">25</xref>). The ion channelling activity of SARS-CoV-2 is prominently maintained by two proteins- (i) E protein (<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R26">26</xref>) and (ii) Orf3a protein (<xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R27">27</xref>). The structure of the pentameric E protein from SARS-CoV-2 has been elucidated by solid state NMR (PDB id: 7K3G) (<xref ref-type="bibr" rid="R26">26</xref>) and homology modelling (<xref ref-type="bibr" rid="R13">13</xref>) which gives insights into its structure-function relationship and selectivity towards cations (<xref ref-type="bibr" rid="R28">28</xref>). Cryo-EM microscopy has given us insights into the dimeric structure of Orf3a (PDB id: 7KJR) which has two well defined aqueous channels fit for cation-selective channelling (<xref ref-type="bibr" rid="R29">29</xref>). Ion channelling mechanism of SARS-CoV-2 viroporins potentially leads to ionic imbalance and pH change of subcellular compartments of the infected host cells causing membrane disruption and intracellular malfunction. The E protein localises in the ERGIC membrane (<xref ref-type="bibr" rid="R27">27</xref>,<xref ref-type="bibr" rid="R30">30</xref>) while Orf3a localises primarily in the endosomal-lysosomal membranes of the human cellular host (<xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R32">32</xref>). Disruption of the ERGIC membrane affects protein translocation and processing of the host cell, causing ER stress (<xref ref-type="bibr" rid="R33">33</xref>) while endosomal- lysosomal membrane rupture leads to total breakdown of host trafficking machinery (<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R32">32</xref>). Ionic imbalance and pH change (<xref ref-type="bibr" rid="R34">34</xref>) by the viroporins are important for the release of the virion particles as well.</p><p id="P3">Inflammatory responses in the host cell leading to ARDS could also be attributed to ionic imbalances (<xref ref-type="bibr" rid="R35">35</xref>). Mutations in pore forming regions of viroporins might lead to loss or gain in function of the ion channel partially or totally along the course of evolution of the viruses. However, the E protein and Orf3a exhibit a high degree of sequence identity between SARS-CoV-2 and its variants. We calculated the position specific frequency of all the residues of Orf3a and E protein using big data analysis to comment on the conservation of the sequences across the SARS-CoV-2 variants. The amino acid changes were identified, aligned and their homology models were structurally superimposed to each other. We inserted the viroporins (E and Orf3a) in organelle specific membrane mimics which allow solute and solvent movement, and performed molecular dynamics simulation studies to understand their mechanism of actions. While studying about the possible consequences, we found significant upregulation in immunomodulatory genes like CD40, IFNL1, IFNL2, IFNL3, IL12A, IL33, IL6 and NFkB1 after analysing the RNA sequencing dataset from Katsura et al., 2020 through our pipeline. Cellular functions like defence response to virus, regulation of cytokine production, response to IFN-γ and regulation of NFκB signalling were implicated in ontology analysis. Indeed, these cellular functions could be directly or indirectly affected by ionic imbalances in the cell, mediated by the viroporins Orf3a and E protein.</p></sec><sec id="S2" sec-type="materials | methods"><label>2</label><title>Materials and methods</title><sec id="S3"><title>Position specific amino acid residue frequency calculation</title><p id="P4">Complete protein sequences were retrieved from NIH source data openly available (NCBI SARS-CoV-2 variant data packages; SARS-CoV-2 Resources - NCBI (nih.gov) and NCBI Virus; NCBI Virus (nih.gov) in the fasta format for different SARS CoV-2 variants. Sequences for the whole proteome from each of the variants were extracted, followed by separating the reading frames into Orf3a and E protein. Once the respective protein sequences for each variant were identified, we used the median length of the sequences as a selection filter. Any reported sequence lesser and greater than the median of the length of all proteins were discarded (incomplete or truncated sequences were hence excluded from the analysis). Indeed, for the proteins in each variant, we computed the following metric:</p><p id="P5">freq(Length protein &lt; Median) * freq(Length protein &gt; Median), and the results were always less than 10e-5.</p><p id="P6">This cut-off resulted in lower probability of having truncated and deleted sequences in our analysis. Using the refined list of amino acid sequences, we built a count matrix for each amino acid at each position for Orf3a and E protein for each variant. Using the count matrix, the positional frequency of each amino acid was computed and the amino acid with the highest frequency at each position was considered as the consensus sequence for the variant. The mutational frequency was calculated from the positional amino acid frequency using the following:</p><p id="P7">Mutational frequency = 1- positional frequency</p><p id="P8">The frequency in this calculation refers to the intra-variant frequency for each protein. All calculations were performed using custom made programs in Python. The data is represented as a heatmap across the different variants of SARS CoV-2 for the positional intra-variant frequency and as a stacked bar plot for the calculated mutational frequency for each amino acid position.</p></sec><sec id="S4"><title>Multiple sequence alignment</title><p id="P9">Consensus amino acid sequences of Orf3a and E protein were computed across the variants Q lineage of Alpha (Q.3), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), AY lineage (AY.103) and Omicron (B.1.1.529). We aligned the variant specific mutation containing sequences with their references (<bold>Orf3a</bold>: NCBI Reference Sequence: YP_009724391.1; <bold>E protein</bold>: NCBI Reference Sequence: YP_009724392.1) in the online alignment tool Clustal Omega (<xref ref-type="bibr" rid="R62">62</xref>) and was visualised with Jalview (<ext-link ext-link-type="uri" xlink:href="http://www.jalview.org">www.jalview.org</ext-link>).</p></sec><sec id="S5"><title>Homology modelling of the Orf3a protein and E protein</title><p id="P10">The structure of the Orf3a protein of SARS-CoV-2 has been elucidated using cryo-EM microscopy and determined as a dimeric protein (PDB id: 7KJR) (<xref ref-type="bibr" rid="R29">29</xref>). This structure has been used as a template for structure-based homology modelling of variant specific Orf3a structures. Pentameric E protein structure has been elucidated using solid state NMR from SARS-CoV-2 (PDB-id: 7K3G) (<xref ref-type="bibr" rid="R26">26</xref>) which has been templated to generate refined structural models for further analysis.</p><p id="P11">All the homology modelling procedures have been performed using MODELLER (<xref ref-type="bibr" rid="R64">64</xref>) and SWISS-MODEL (<xref ref-type="bibr" rid="R65">65</xref>). Model refinement and further structural fine-tuning of unreliable structural regions were done using the GalaxyWeB server (<xref ref-type="bibr" rid="R66">66</xref>). The structures obtained were validated by scores obtained from the MolProbity (<xref ref-type="bibr" rid="R67">67</xref>,<xref ref-type="bibr" rid="R68">68</xref>). The structures were chosen by comparing predominantly the different parameters like percentage of Ramachandran favoured and unfavoured residues, percentage of favoured and unfavoured rotamers, Mol-Probity score, and Clash Score, validating the quality of the modelled structures.</p></sec><sec id="S6"><title>Generation of the protein-membrane system</title><p id="P12">The transmembrane region of the proteins: Orf3a and Envelope (E) protein, was extracted and used for insertion in respective membrane mimics depending on their cellular localization. Orf3a from SARS-Cov-2 was inserted into an endosome mimicking membrane. The E protein was inserted into a membrane similar to the ERGIC. Asymmetric lipid compositions were maintained in the endosome and ERGIC mimicking systems. All the membrane insertion processes were performed in the CHARMM-GUI web server (<xref ref-type="bibr" rid="R69">69</xref>,<xref ref-type="bibr" rid="R70">70</xref>) similar to our previous study (<xref ref-type="bibr" rid="R13">13</xref>). The pore water of each of these channel proteins was removed while preparing the protein-membrane systems in CHARMM-GUI. The lipid compositions of each system corresponding to their inserted proteins are listed as follows:</p></sec><sec id="S7"><title>Molecular dynamics simulations using NAMD and VMD</title><p id="P13">The protein membrane systems were solvated using a 12 Å thick patch of TIP3P (<xref ref-type="bibr" rid="R71">71</xref>) waters at both sides of the protein bilayer complex along the <italic>z</italic> axis, and a uniform hexagonal area was maintained in the <italic>x</italic>–<italic>y</italic> plane. The K<sup>+</sup> ion was added to the solvated system as required to mimic 0.15 M KCl which is similar to our physiological concentration of K<sup>+</sup> ion. The structural models of proteins and lipids were presented using the CHARMM36 force field parameters (<xref ref-type="bibr" rid="R72">72</xref>,<xref ref-type="bibr" rid="R73">73</xref>) and NAMD 2.12 (<xref ref-type="bibr" rid="R74">74</xref>,<xref ref-type="bibr" rid="R75">75</xref>) was used to run the molecular dynamics (MD) simulations. Firstly, the energy of each system was minimised and then equilibrated using the NVT ensemble for 40 ps. The integration time step was kept at 1 fs with harmonic restraints of 10 kcal mol<sup>–1</sup> Å<sup>–2</sup> on the protein atoms and 5 kcal mol<sup>–1</sup> Å<sup>–2</sup> on the lipid headgroups. These are the first two steps of minimization and initial equilibration of the simulation system. Several cycles of NPT equilibration (four or more) were carried out after the first two steps with reducing force constants in each cycle to relax the restraints on the protein-membrane simulation system. The entire energy minimization and equilibration steps add up to around 2.25 ns for each simulation run. The minimised and equilibrated protein-membrane system was then simulated for 5 ns using an integrating time step of 2 fs, constraining all H-containing bonds by the SHAKE algorithm (<xref ref-type="bibr" rid="R76">76</xref>). The total sampling time of the trajectories altogether added to ~20 ns. Langevin dynamics was used in all the simulations to keep the temperature constant at 303 K with a damping coefficient of 1 ps<sup>–1</sup>, and the Langevin piston method was used in NPT ensembles to keep the pressure constant at 1 atm with a coupling constant of τP = 0.5 ps (<xref ref-type="bibr" rid="R77">77</xref>). In all these simulations, short-range nonbonded interactions were switched off between 10 and 12 Å. The Particle Mesh Ewald method (<xref ref-type="bibr" rid="R78">78</xref>) was employed with a grid size of 1 Å for the estimation of long-range electrostatic interactions. The total energy of the simulation system, number of H-bonds, RMSD, RMSF and solvent accessible surface area (SASA) of specific pore forming residues were analysed with respect to time steps as obtained from the results of the NAMD simulation in VMD (<xref ref-type="bibr" rid="R79">79</xref>) interface and snapshots of the timesteps were represented and visualised using Chimera 1.10 (<xref ref-type="bibr" rid="R80">80</xref>).</p></sec><sec id="S8"><title>Transcriptomic analysis</title><p id="P14">Transcriptomic data was reanalyzed from the following source: <italic>Katsura et al., 2020 Cell Stem Cell</italic> (<xref ref-type="bibr" rid="R36">36</xref>). The data is derived from whole genome RNA sequencing from a modular alveolo-sphere culture system of human alveolar type 2 cells/pneumocytes derived from primary lung tissue (<xref ref-type="bibr" rid="R36">36</xref>). Data was downloaded from Gene Expression Omnibus library [ID: GSE152586] and pre-processing of the fastq files was performed. Details of data extraction and experimental procedures are available in the original publication: <italic>Katsura et al., 2020 Cell Stem Cell</italic>. The DESeq2 package in R BioConductor (<ext-link ext-link-type="uri" xlink:href="http://www.bioconductor.org/packages/release/bioc/html/DESeq2.html">http://www.bioconductor.org/packages/release/bioc/html/DESeq2.html</ext-link>) was used to analyse the data. The normalised data was used for visualisation, and differential analysis of the count data (<xref ref-type="bibr" rid="R81">81</xref>). The DESeq2 data class consists of a count matrix with rows corresponding to genes and columns denoting experimental samples (control and COVID-19). For dimensional reduction and outlier identification, we performed a principal component analysis (PCA) on the DESeq2 data class of count reads. The details of the <italic>DESeq2</italic> pipeline are discussed in detail in <italic>Love et al., 2014 Genome Biology</italic> (<xref ref-type="bibr" rid="R81">81</xref>). Briefly, <italic>DESeq2</italic> package models the data counts on the count matrix using a gamma-Poisson distribution with mean (normalised concentration of cDNA fragments from the gene in a sample). The size factors are determined by the median-of-ratios method. For each gene, a generalised linear model (GLM), which returns overall expression strength of the gene, log<sub>2</sub> of the fold change (LFC) between the two groups compared. The p values of comparison between control and infected samples are adjusted for multiple testing using the Benjamini and Hochberg procedure.</p><p id="P15">To identify the processes encoded by the upregulated genes, we used the publicly available protocol in Metascape (<ext-link ext-link-type="uri" xlink:href="http://www.metascape.org/">www.metascape.org/</ext-link>; (<xref ref-type="bibr" rid="R82">82</xref>)). We annotated the functions encoded by the genes using the following gene ontology enrichment: Biological processes, Cellular components, Molecular components, KEGG pathway and Reactome pathways. Metascape combines functional enrichment, interactome analysis, gene annotation, and membership search to leverage over 40 independent knowledge bases. The minimum overlap was kept at 3, the p value cut-off at 0.01 and the minimum enrichment was kept at 1.5. The network type was set at full network, network edges defined by confidence of the highest threshold (90%).</p></sec><sec id="S9"><title>Statistical analysis</title><p id="P16">For statistical comparisons, we have used Kolmogorov-Smirnov (KS) Test for comparing the cumulative distributions and unpaired students’ t-test for comparison between different conditions. The p-values reported in this paper consider p &lt; 0.05 to be statistically significant.</p></sec></sec><sec id="S10" sec-type="results"><label>3</label><title>Results</title><sec id="S11"><label>3.1</label><title>Intra-variant sequence analysis of SARS-CoV-2 viroporins, Orf3a and Envelope (E) protein</title><p id="P17">We have developed a new analytical program to identify invariant sequences conserved among the currently sequenced genomes of SARS CoV-2 in light of Orf3a and E protein (<xref ref-type="fig" rid="F1">Figure 1A</xref>). We extracted the sequences of Orf3a and E proteins from the following variants respectively: Alpha (B.1.1.7; <xref ref-type="fig" rid="F1">Figure 1B</xref>; N = 105187 and 105169), Q lineage of Alpha (Q.3; <xref ref-type="fig" rid="F1">Figure 1B</xref>; N = 5300 and 5293) Beta (B.1.351; <xref ref-type="fig" rid="F1">Figure 1B</xref>; N = 3814 and 3209), Gamma (P.1; <xref ref-type="fig" rid="F1">Figure 1B</xref>; N = 13593 and 13558), Delta (B.1.617.2; <xref ref-type="fig" rid="F1">Figure 1B</xref>; N = 50397 and 50198), AY lineage of Delta (AY.103; <xref ref-type="fig" rid="F1">Figure 1B</xref>; N = 48918 in both the proteins), Omicron (B.1.1.529; <xref ref-type="fig" rid="F1">Figure 1B</xref>; N = 468 in both the proteins) and BA lineage of Omicron (BA.1.1; <xref ref-type="fig" rid="F1">Figure 1B</xref>; N = 167839 in both the proteins). Sequences greater than or equal to the median length were used for creating the count matrix (<xref ref-type="fig" rid="F1">Figure 1B</xref>). The count matrix generated for Orf3a intra-variant position-specific frequency for each amino acid showed certain positions to have lower frequencies compared to a stable score of 1 (<xref ref-type="fig" rid="F1">Figure 1C</xref>). This fluctuation in position specific frequencies was very low (range: 0- 0.148), and hence could not be assigned as a stable mutation (<xref ref-type="fig" rid="F1">Figure 1D</xref>). In order to ascertain the stability of mutations observed, we calculated the consensus sequences for Orf3a and E protein for each variant. Additionally, a similar count matrix generated for E protein intra-variant position-specific frequency also showed lower frequencies in certain positions compared to a stable score of 1 (<xref ref-type="fig" rid="F1">Figure 1E</xref>). The fluctuation in position specific frequencies was quite low (range: 0- 0.064), much lower than its Orf3a counterpart (<xref ref-type="fig" rid="F1">Figure 1F</xref>).</p><p id="P18">We computed the position-specific residue frequency and observed the position S26L of Orf3a in B.1.617.2 (Delta) and T9I of E protein in B.1.1.529 (Omicron) and BA.1.1 (BA lineage of Omicron), to have relatively higher scores (<xref ref-type="fig" rid="F1">Figure 1D, F</xref>).</p></sec><sec id="S12"><label>3.2</label><title>Structural modelling and analysis of representative mutations in Orf3a across SARS-CoV-2 variants</title><p id="P19">In correlation to previous results, we have identified representative mutations across Orf3a sequence specific for different SARS-CoV-2 variants (<xref ref-type="fig" rid="F2">Figure 2A</xref>). All the variants except the Alpha, have one or more random mutations. The structure of Orf3a dimer has been elucidated using Cryo-EM at 2.1 angstrom, which spans from 40<sup>th</sup> to 236<sup>th</sup> amino acid, in complex with human apolipoprotein A (PDB id: 7KJR). The dimeric structure of Orf3a was extracted from the pdb file which was used as the reference (<xref ref-type="fig" rid="F2">Figure 2B</xref>) for homology modelling of the representative Orf3a structures across SARS-CoV-2 variants (<xref ref-type="supplementary-material" rid="SD1">Supplementary figure 1</xref>). The refined Orf3a structures of the variants with the best parameters i.e.- Clash score, Molprobity score, Ramachandran outliers, Rotamer outliers, were chosen for further analysis of structural overlap. The Orf3a reference structure was superimposed on modelled structures from Alpha (B.1.1.7; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1A</xref>; RMSD = 0.89; TM score = 0.953), Q lineage of Alpha (Q.3; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1B</xref>; RMSD = 1.14 ; TM score = 0.945) Beta (B.1.351; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1C</xref>; RMSD = 1.19 ; TM score = 0.942), Gamma (P.1; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1D</xref>; RMSD = 0.84 ; TM score = 0.954), Delta (B.1.617.2; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1E</xref>; RMSD = 0 ; TM score = 1), AY lineage of Delta (AY.103; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1F</xref>; RMSD = 1.10 ; TM score = 0.945), Omicron (B.1.1.529; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1G</xref>; RMSD = 0.90 ; TM score = 0.952) and BA lineage of Omicron (BA.1.1; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1H</xref>; RMSD = 0.96 ; TM score = 0.951). The reference structures are shown in orange and the variants are shown in cyan (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1</xref>). According to our previous result, the Alpha and BA sub-lineage of Omicron do not have any significant mutations. In other variants, the following representative mutations were analysed in the Orf3a dimer overlap across variants: Beta- Q57H (<xref ref-type="fig" rid="F2">Figure 2C-i</xref>; RMSD = 1.19; TM score = 0.942), S171L (<xref ref-type="fig" rid="F2">Figure 2C-ii</xref>; RMSD = 1.19; TM score = 0.942); AY lineage of Delta- P104S (<xref ref-type="fig" rid="F2">Figure 2C-iii</xref>; RMSD = 1.10 ; TM score = 0.945); Omicron- L106F (<xref ref-type="fig" rid="F2">Figure 2C-iv</xref>; RMSD = 0.90 ; TM score = 0.952), S165F (<xref ref-type="fig" rid="F2">Figure 2C-v</xref>; RMSD = 0.90 ; TM score = 0.952). However, the mutations present in the gamma (S253P) and delta variant (S26L) of Orf3a are in positions not included in the cryo-EM reference structure (40-236) and thus could not be mapped. The TM-score matrix indicates that there is no major structural variability in Orf3a protein among the variants (<xref ref-type="fig" rid="F2">Figure 2D</xref>).</p></sec><sec id="S13"><label>3.3</label><title>Molecular dynamics simulation of the TM region of Orf3a (40-125) from SARS-CoV-2 in endosomal membrane mimicking system</title><p id="P20">The SARS-CoV-2 Orf3a dimeric protein structure has been determined using cryo-EM at 2.0 angstroms resolution (PDB id: 7KJR) (<xref ref-type="bibr" rid="R29">29</xref>). The transmembrane region of the protein ranges from 40 to 125th residue of the protein. We performed membrane insertion of the truncated structure of Orf3a (40-125) using CHARMM-GUI. It comprises lipid components mimicking the human endosomal membrane (<xref ref-type="table" rid="T1">Table 1</xref>). Then a molecular dynamics simulation of 5 ns was performed using NAMD to understand the channelling activity of the upper and lower channels of the protein (<xref ref-type="supplementary-material" rid="SD1">Supplementary Movie 1</xref>). We observed the presence of the upper channel in the protein-membrane system (<xref ref-type="fig" rid="F3">Figure 3A</xref>-black dotted circle). The water dynamics were observed at regular intervals of 0.5 ns for 2 ns from the initial timestep starting at 0 ns (<xref ref-type="fig" rid="F3">Figure 3Bi</xref>), 0.5 ns (<xref ref-type="fig" rid="F3">Figure 3Bii</xref>), 1 ns (<xref ref-type="fig" rid="F3">Figure 3Biii</xref>), 1.5 ns (<xref ref-type="fig" rid="F3">Figure 3Biv</xref>), and 2 ns (<xref ref-type="fig" rid="F3">Figure 3Bv</xref>). Similarly, the lower channel (<xref ref-type="fig" rid="F3">Figure 3C</xref>-black dotted circle) was also observed at similar timesteps (<xref ref-type="fig" rid="F3">Figure 3i-v</xref>). We calculated the number of H-bonds (<xref ref-type="fig" rid="F3">Figure 3E</xref>), RMSD (<xref ref-type="fig" rid="F3">Figure 3F</xref>), total energy (<xref ref-type="fig" rid="F3">Figure 3G</xref>), and RMSF (<xref ref-type="fig" rid="F3">Figure 3H</xref>) for 5 ns of the simulation. The RMSD remained below 2.5 angstroms ((<xref ref-type="fig" rid="F3">Figure 3F</xref>), indicating that the protein-membrane system has low structural variability. In addition, the total energy of the system remains largely unchanged at -5.7x10<sup>4</sup> kcal/mol (<xref ref-type="fig" rid="F3">Figure 3G</xref>) throughout the time period of the simulation.</p></sec><sec id="S14"><label>3.4</label><title>Molecular dynamics of the TM region of SARS-CoV-2 E protein in an ERGIC membrane mimic shows water movement</title><p id="P21">The pentameric E protein from the SARS-CoV-2 has been modelled taking its solid-state NMR structure as the template (PDB id: 7K3G) (<xref ref-type="bibr" rid="R26">26</xref>), whose viroporin activity through the single channel formed by its TM region (8-40) has been analysed in a previous study (<xref ref-type="bibr" rid="R13">13</xref>) (<xref ref-type="fig" rid="F4">Figure 4A</xref>). The protein-membrane complex was equilibrated energetically followed by 5 ns of MD simulation to analyse the continuous water channel formation through the proposed pore (<xref ref-type="supplementary-material" rid="SD1">Supplementary Movie 2</xref>). The water dynamics was observed at several intervals for 2 ns from the initial timestep starting at 0 ns (<xref ref-type="fig" rid="F4">Figure 4Bi</xref>), 0.5 ns (<xref ref-type="fig" rid="F4">Figure 4Bii</xref>), 1 ns (<xref ref-type="fig" rid="F4">Figure 4Biii</xref>), 1.1 ns (<xref ref-type="fig" rid="F4">Figure 4Biv</xref>), 1.2 ns (<xref ref-type="fig" rid="F4">Figure 4Bv</xref>), 1.3 ns (<xref ref-type="fig" rid="F4">Figure 4Bvi</xref>), 1.4 ns (<xref ref-type="fig" rid="F4">Figure 4Bvii</xref>), 1.5 ns (<xref ref-type="fig" rid="F4">Figure 4Bviii</xref>), and 2 ns ((<xref ref-type="fig" rid="F4">Figure 4Bix</xref>). We observed that from 1 ns to 1.5 ns, the water molecules reach the proposed F26 bottleneck region (<xref ref-type="bibr" rid="R13">13</xref>) inside the pore of the E protein (<xref ref-type="fig" rid="F4">Figure 4Biii-viii</xref>). We calculated the number of H-bonds (<xref ref-type="fig" rid="F4">Figure 4C</xref>), RMSD (<xref ref-type="fig" rid="F4">Figure 4D</xref>), total energy (<xref ref-type="fig" rid="F4">Figure 4E</xref>), and RMSF (<xref ref-type="fig" rid="F4">Figure 4F</xref>) for 5 ns of the simulation. The RMSD remained well below 5 angstroms (<xref ref-type="fig" rid="F4">Figure 4D</xref>), indicating that the protein-membrane system has high structural stability. In addition, the total energy of the system remains relatively unfluctuating around -3.2 x10<sup>4</sup> kcal/mol (<xref ref-type="fig" rid="F4">Figure 4E</xref>) throughout the time period of the simulation.</p></sec><sec id="S15"><label>3.5</label><title>Upregulated genes in COVID condition reflects cellular processes impacted by ion channelling activity</title><p id="P22">We used whole genome RNA sequencing data (<xref ref-type="bibr" rid="R36">36</xref>) to explore genes upregulated in SARS-CoV-2 infection, and whether they could be impacted by changes in cellular ionic homeostasis. PCA analysis (<xref ref-type="fig" rid="F5">Figure 5A</xref>) suggested that uninfected controls and SARS-CoV-2 infected samples were mutually orthogonal to each other, suggesting that gene expression levels were indeed due to the infection. The first component explained 53% of the observed variance in the expression patterns. We further looked into the proportion of upregulated and downregulated genes (<xref ref-type="fig" rid="F5">Fig 5B, 5C</xref>), and found 563 significantly upregulated genes and 75 significantly downregulated genes. The log of fold change (LFC) after the DESEQ2 pipeline was set at a minimum of 2, and adjusted p-value was set at 0.01. The top 50 upregulated and downregulated genes are shown in <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2</xref>. PRKAA1 was upregulated in the infected samples, albeit it did not clear the threshold of LFC &gt; 2 (<xref ref-type="fig" rid="F5">Figure 5D</xref>) and interestingly, had been shown to regulate ion channelling activity of the host cell (<xref ref-type="bibr" rid="R37">37</xref>). We also observed significant upregulation in immunomodulatory genes like CD40, IFNL1, IFNL2, IFNL3, IL12A, IL33, IL6 and NFkB1 (<xref ref-type="fig" rid="F5">Figure 5E</xref>).</p><p id="P23">Among the downregulated genes were HSP90AB1, HSP90AA1 and HSP90B1 (<xref ref-type="fig" rid="F5">Figure 5F</xref>). In our analysis, we focused on those genes only that could be impacted by or otherwise could impact cellular ion channelling and ionic concentration. In our analysis, 88% of the genes were upregulated while 12% were downregulated with our parameters (<xref ref-type="fig" rid="F5">Figure 5G</xref>). In order to understand what cellular and molecular functions could be impacted by the upregulated genes, we constructed a gene network using Metascape (<xref ref-type="fig" rid="F5">Figure 5H</xref>). The major functions implicated are defence response to virus, immune response regulating signalling pathway, response to IFN-β, regulation of cytokine production, response to IFN-γ, lymphocyte activation, SARS-CoV-2 innate immunity evasion, and regulation of I-κB-kinase/NFκB signalling (<xref ref-type="fig" rid="F5">Figure 5H</xref>). All these processes imply the active participation and activation of the host defence system in case of a viral infection. We also evaluated the functional significance of protein-protein interactions of the upregulated genes and found that the following functions were enriched: defence response to virus, IFN-α/β signalling, cytokine signalling, post translational protein phosphorylation, calcium signalling pathway- Gα(q) signalling, PI3K-Akt-mTOR signalling, exocytosis and complement cascades (<xref ref-type="fig" rid="F5">Figure 5I</xref>). Indeed, a lot of these functionalities could be directly or indirectly affected by ionic imbalances in the cell. These observations provide strength to our hypothesis that ion channelling activity by viroporins is responsible for viral pathogenesis and host cell responses in SARS-CoV-2.</p></sec></sec><sec id="S16" sec-type="discussion"><label>4</label><title>Discussion</title><p id="P24">Ion channelling activity is an important cellular event taking place in all organisms, from unicellular prokaryotes to multicellular eukaryotes like humans. Human cellular organisation and mechanisms of varied physiological events are directly or indirectly influenced by ion channels, which are mostly specific for the type of ion it transports. Almost all families of viruses encode one or more ion channel proteins which integrate in the host membrane and regulate key viral life cycle events like virion maturation, assembly and release. Viroporins oligomerize in the host membranes, leading to formation of permeable hydrophilic pores (<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R38">38</xref>), which alters cellular ionic homeostasis in hosts. It leads to membrane depolarization and disruption of organelle architecture <italic>via</italic> membrane remodelling events, alteration of Ca<sup>2+</sup> homeostasis (<xref ref-type="bibr" rid="R39">39</xref>) and protein trafficking.</p><p id="P25">SARS-CoV-2 has acquired several mutation hotspots in the Spike (S) protein across all its variants (<xref ref-type="bibr" rid="R40">40</xref>,<xref ref-type="bibr" rid="R41">41</xref>) which contributes to the increased pathogenicity of the variants (<xref ref-type="bibr" rid="R17">17</xref>). However, there are several other important viral proteins which play decisive roles in the viral life cycle and have remained conserved across the variants. We performed large scale sequence data analysis for the ion channelling viral proteins of SARS-CoV-2: Orf3a and Envelope protein, where we calculated the position specific frequency of each amino acid from sequences reported in the NCBI datasets for these two proteins. The positions harbouring the mutations reported from the analysis, were either identical to the residue in the corresponding position of the reference sequence with lower frequency, or different residue with higher frequency. These changes are random mutations and cannot be concluded as significant, as the sample space of the number of sequences were quite low in some of the variants. The variants with the highest number of sequences (Alpha and BA lineage of Omicron - <xref ref-type="fig" rid="F1">Figure 1B</xref>) did not show any major mutations in the proteins. Nevertheless, we aligned the sequences of the variants and specified the random mutations in the ion channel forming region of the proteins. All the mutant structures were structurally aligned with the reference structure (PDB id: 7KJR) which showed no significant structural variability in the channel forming region. Afterwards, we looked into the membrane permeation and channel-forming mechanism of the Orf3a and E protein from SARS-CoV-2.</p><p id="P26">One of the most studied viroporins is the M2 channel of the influenza virus which is essential for viral replication and homeostasis. The M2 channel allows K<sup>+</sup> ion influx and disrupts Na<sup>+</sup>/K<sup>+</sup> ionic homeostasis in the late endosomes. It also acts as a proton channel in the TGN (pH~6) which affects downstream protein trafficking machinery (<xref ref-type="bibr" rid="R42">42</xref>). The NS4A channel of HCV localises on the mitochondrial membrane and disrupts mitochondrial architecture by causing ionic imbalance in the organelle lumen (<xref ref-type="bibr" rid="R43">43</xref>). Viroporins activate apoptosis through the mitochondrial pathway via formation of apoptosome with pro-caspase 9 and apoptosis protease-activating factor-1 (<xref ref-type="bibr" rid="R44">44</xref>). P7 viroporin of HCV is a gated proton channel which causes H<sup>+</sup> efflux, resulting in IL-1β production (<xref ref-type="bibr" rid="R45">45</xref>). The E protein of SARS-CoV-2 has been reported to rescue growth of K<sup>+</sup>-uptake deficient bacteria thus supporting its K<sup>+</sup> conductivity. Additionally, it acts as a proton channel and causes bacterial cell death due to increased membrane permeabilization (<xref ref-type="bibr" rid="R28">28</xref>).</p><p id="P27">However, the exact molecular mechanism of these ion channelling events needs further exploration from a structural point of view. Our results demonstrate salient structural features which might determine how the viroporin functions. Hydrophilic pore formation is one of the fundamental features of a viroporin (<xref ref-type="bibr" rid="R23">23</xref>). We show formation of hydrophilic pore <italic>via</italic> water channel formation which could imply formation of ionic transfer mediums across the membranes. Such a passage medium through the upper and lower channels of dimeric Orf3a of SARS-CoV-2 is observed in human endosomal mimicking membranes. Endosome is an important structural organelle involved in a wide range of cellular functions. Water chain formation through the central pentameric pore of the Envelope (E) protein up to the proposed bottleneck region, defined the hydrophilic pathways through this viroporin of SARS-CoV-2 in human ERGIC membrane mimic.</p><p id="P28">The question remains, what impact do these viroporins impart at a physiological level? Indeed, our studies are <italic>in silico</italic> and have limitations of being non-experimental from an <italic>in vitro</italic> and <italic>in vivo</italic> standpoint. However, the impact of ionic imbalances in cellular micro-environment as a result of viral infections and viroporins have been studied in great detail earlier. One immediate observation comes from the previous SARS strain, the SARS-CoV-1 which showed that E protein localised in the ERGIC membrane, and facilitated the movement of Ca<sup>2+</sup> ions into the cytosol (<xref ref-type="bibr" rid="R24">24</xref>). On the other hand, the Orf3a localised at the Endosome, Golgi apparatus and the plasma membrane transport K<sup>+</sup> ions (<xref ref-type="bibr" rid="R46">46</xref>). A tight regulation of cationic and anionic ion channels controls the ionic homeostasis in the airways which can be correlated to complex pathological features in lung diseases (<xref ref-type="bibr" rid="R47">47</xref>). Viroporins localised in the subcellular membranes of these lung airway epithelial cells is the primary cause of ionic imbalance and thus can be potential therapeutic targets against ARDS, which is the primary reason for fatality in SARS-CoV-2 infection (<xref ref-type="bibr" rid="R48">48</xref>,<xref ref-type="bibr" rid="R49">49</xref>). Transcriptomics analysis from SARS-CoV-2 infected samples showed an upregulation in inflammatory response mediated by several interleukins and interferons (<xref ref-type="bibr" rid="R50">50</xref>) which are probably regulated by NFκB (<xref ref-type="bibr" rid="R51">51</xref>). Increase in CD40 (<xref ref-type="bibr" rid="R52">52</xref>), IL-6 (<xref ref-type="bibr" rid="R53">53</xref>), IL-12 (<xref ref-type="bibr" rid="R54">54</xref>) and IL-33 (<xref ref-type="bibr" rid="R55">55</xref>) transcripts strongly correlate with similar expression patterns of differentially expressed genes in Acute Lung Injury, ARDS and pulmonary fibrosis. NF-kB signalling has also been shown to be activated and induce inflammatory cytokines and chemokines, including IL-1b, IL-18, and IL-8 (<xref ref-type="bibr" rid="R56">56</xref>–<xref ref-type="bibr" rid="R58">58</xref>). AMPK is a master regulator of a wide spectrum of ion channels, carrier proteins and symporter-pumps (<xref ref-type="bibr" rid="R37">37</xref>), differential expression of which can impact their stimulatory and inhibitory effects (<xref ref-type="bibr" rid="R59">59</xref>). These channels, carrier proteins and/or pumps mediate the primary host cell response against viroporin action. Downregulation of ion channels is also known to be impacted by their interactions with Hsp proteins such as Kv7.4, a voltage gated potassium channel (<xref ref-type="bibr" rid="R60">60</xref>). Indeed, Hsp90, being a part of the protein folding machinery showed lower expression levels, probably due to disruption of the ERGIC and endosomal compartment. This is in line with our initial membrane disruption hypothesis as a result of change in ionic balance of the cell. In accordance with our study, E protein-mediated Ca<sup>2+</sup> and K<sup>+</sup> leakage, and Orf3-mediated K<sup>+</sup> efflux could be a vital factor causing cellular ionic imbalance activating the NLRP3 inflammasome since, the activation of NLRP3 inflammasome directly correlates with the observed viroporin activity (<xref ref-type="bibr" rid="R46">46</xref>,<xref ref-type="bibr" rid="R61">61</xref>). Ionic imbalance in cells can promote build-up of reactive oxygen species (ROS) in the mitochondria, providing indirect to activation of NLRP3 (<xref ref-type="bibr" rid="R46">46</xref>). Our multivariate study on SARS-CoV-2 viroporins gives valuable structural insights into their mechanism of actions. We have elucidated the importance of Orf3a and E protein in COVID-19 pathogenesis on a structure-function association, potentially translating to changes in the transcriptome of the host cell. Further investigation along these lines can reveal potential therapeutic strategies against SARS-CoV-2.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Figure 1</label><media xlink:href="EMS135919-supplement-Supplementary_Figure_1.jpg" mimetype="image" mime-subtype="jpeg" id="d572aAdEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Supplementary Figure 2</label><media xlink:href="EMS135919-supplement-Supplementary_Figure_2.jpg" mimetype="image" mime-subtype="jpeg" id="d572aAdEcB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><label>Supplementary materials</label><media xlink:href="EMS135919-supplement-Supplementary_materials.pdf" mimetype="application" mime-subtype="pdf" id="d572aAdEdB" position="anchor"/></supplementary-material></sec></body><back><ack id="S17"><title>Funding</title><p id="P29">MS, VH and SS are members of MedInsights. Internal funding was used to support basic research presented in this manuscript. No external funding agency had any role in the idea and experimental design, model execution and evaluation, and drafting figures and manuscript.</p></ack><sec id="S18" sec-type="data-availability"><title>Data Availability Statement</title><p id="P30">All our data are available upon request to corresponding authors</p></sec><fn-group><fn id="FN1" fn-type="con"><p id="P31"><bold>Authorship contribution statement</bold></p><p id="P32">Manish Sarkar &amp; Soham Saha (co-correspondence): Study design, structural modelling, molecular dynamics and analysis, bioinformatics. MS and SS drafted the manuscript and made the final figures.</p><p id="P33">Victor Hannothiaux: Data curation, big data analysis, residue frequency calculations, coding.</p><p id="P34">Paul Etheimer: Designed analysis automation for whole genome metagenome analysis using DeSEQ2 pipeline and performed the analysis on the transcriptomic data.</p></fn><fn id="FN2"><p id="P35"><bold>Institutional Review Board Statement: N/A</bold></p></fn><fn id="FN3"><p id="P36"><bold>Informed Consent Statement: N/A</bold></p></fn><fn id="FN4" fn-type="conflict"><p id="P37"><bold>Conflicts of Interest</bold></p><p id="P38">Authors declare no competing interests. Only publicly available libraries, servers, and resources were employed for the entire study. All data in the main text or the supplementary materials are unconditionally available upon request. Any codes/pipelines designed are proprietary to Medinsights.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voysey</surname><given-names>M</given-names></name><name><surname>Clemens</surname><given-names>SAC</given-names></name><name><surname>Madhi</surname><given-names>SA</given-names></name><name><surname>Weckx</surname><given-names>LY</given-names></name><name><surname>Folegatti</surname><given-names>PM</given-names></name><name><surname>Aley</surname><given-names>PK</given-names></name><etal/></person-group><article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</article-title><source>The Lancet</source><year>2021</year><month>Jan</month><volume>397</volume><issue>10269</issue><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="pmcid">PMC7723445</pub-id><pub-id pub-id-type="pmid">33306989</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32661-1</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baden</surname><given-names>LR</given-names></name><name><surname>El Sahly</surname><given-names>HM</given-names></name><name><surname>Essink</surname><given-names>B</given-names></name><name><surname>Kotloff</surname><given-names>K</given-names></name><name><surname>Frey</surname><given-names>S</given-names></name><name><surname>Novak</surname><given-names>R</given-names></name><etal/></person-group><article-title>Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine</article-title><source>N Engl J Med</source><year>2021</year><month>Feb</month><day>4</day><volume>384</volume><issue>5</issue><fpage>403</fpage><lpage>16</lpage><pub-id pub-id-type="pmcid">PMC7787219</pub-id><pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polack</surname><given-names>FP</given-names></name><name><surname>Thomas</surname><given-names>SJ</given-names></name><name><surname>Kitchin</surname><given-names>N</given-names></name><name><surname>Absalon</surname><given-names>J</given-names></name><name><surname>Gurtman</surname><given-names>A</given-names></name><name><surname>Lockhart</surname><given-names>S</given-names></name><etal/></person-group><article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</article-title><source>N Engl J Med</source><year>2020</year><month>Dec</month><day>31</day><volume>383</volume><issue>27</issue><fpage>2603</fpage><lpage>15</lpage><pub-id pub-id-type="pmcid">PMC7745181</pub-id><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>EJ</given-names></name><name><surname>Angulo</surname><given-names>FJ</given-names></name><name><surname>McLaughlin</surname><given-names>JM</given-names></name><name><surname>Anis</surname><given-names>E</given-names></name><name><surname>Singer</surname><given-names>SR</given-names></name><name><surname>Khan</surname><given-names>F</given-names></name><etal/></person-group><article-title>Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data</article-title><source>The Lancet</source><year>2021</year><month>May</month><volume>397</volume><issue>10287</issue><fpage>1819</fpage><lpage>29</lpage><pub-id pub-id-type="pmcid">PMC8099315</pub-id><pub-id pub-id-type="pmid">33964222</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00947-8</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadoff</surname><given-names>J</given-names></name><name><surname>Gray</surname><given-names>G</given-names></name><name><surname>Vandebosch</surname><given-names>A</given-names></name><name><surname>Cárdenas</surname><given-names>V</given-names></name><name><surname>Shukarev</surname><given-names>G</given-names></name><name><surname>Grinsztejn</surname><given-names>B</given-names></name><etal/></person-group><article-title>Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19</article-title><source>N Engl J Med</source><year>2021</year><month>Jun</month><day>10</day><volume>384</volume><issue>23</issue><fpage>2187</fpage><lpage>201</lpage><pub-id pub-id-type="pmcid">PMC8220996</pub-id><pub-id pub-id-type="pmid">33882225</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2101544</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Duan</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials</article-title><source>JAMA</source><year>2020</year><month>Sep</month><day>8</day><volume>324</volume><issue>10</issue><fpage>951</fpage><pub-id pub-id-type="pmcid">PMC7426884</pub-id><pub-id pub-id-type="pmid">32789505</pub-id><pub-id pub-id-type="doi">10.1001/jama.2020.15543</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>G</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Chu</surname><given-names>K</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title><source>The Lancet Infectious Diseases</source><year>2021</year><month>Feb</month><volume>21</volume><issue>2</issue><fpage>181</fpage><lpage>92</lpage><pub-id pub-id-type="pmcid">PMC7832443</pub-id><pub-id pub-id-type="pmid">33217362</pub-id><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30843-4</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asghari</surname><given-names>A</given-names></name><name><surname>Naseri</surname><given-names>M</given-names></name><name><surname>Safari</surname><given-names>H</given-names></name><name><surname>Saboory</surname><given-names>E</given-names></name><name><surname>Parsamanesh</surname><given-names>N</given-names></name></person-group><article-title>The Novel Insight of SARS-CoV-2 Molecular Biology and Pathogenesis and Therapeutic Options</article-title><source>DNA and Cell Biology</source><year>2020</year><month>Oct</month><day>1</day><volume>39</volume><issue>10</issue><fpage>1741</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">32716648</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cevik</surname><given-names>M</given-names></name><name><surname>Kuppalli</surname><given-names>K</given-names></name><name><surname>Kindrachuk</surname><given-names>J</given-names></name><name><surname>Peiris</surname><given-names>M</given-names></name></person-group><article-title>Virology, transmission, and pathogenesis of SARS-CoV-2</article-title><source>BMJ</source><year>2020</year><month>Oct</month><day>23</day><elocation-id>m3862</elocation-id><pub-id pub-id-type="pmid">33097561</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redondo</surname><given-names>N</given-names></name><name><surname>Zaldívar-López</surname><given-names>S</given-names></name><name><surname>Garrido</surname><given-names>JJ</given-names></name><name><surname>Montoya</surname><given-names>M</given-names></name></person-group><article-title>SARS-CoV-2 Accessory Proteins in Viral Pathogenesis: Knowns and Unknowns</article-title><source>Front Immunol</source><year>2021</year><month>Jul</month><day>7</day><volume>12</volume><elocation-id>708264</elocation-id><pub-id pub-id-type="pmcid">PMC8293742</pub-id><pub-id pub-id-type="pmid">34305949</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.708264</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvas</surname><given-names>JA</given-names></name><name><surname>Vasquez</surname><given-names>DM</given-names></name><name><surname>Park</surname><given-names>JG</given-names></name><name><surname>Chiem</surname><given-names>K</given-names></name><name><surname>Allué-Guardia</surname><given-names>A</given-names></name><name><surname>Garcia-Vilanova</surname><given-names>A</given-names></name><etal/></person-group><article-title>Contribution of SARS-CoV-2 Accessory Proteins to Viral Pathogenicity in K18 Human ACE2 Transgenic Mice</article-title><source>J Virol</source><year>2021</year><month>Aug</month><day>10</day><volume>95</volume><issue>17</issue><elocation-id>e0040221</elocation-id><pub-id pub-id-type="pmcid">PMC8354228</pub-id><pub-id pub-id-type="pmid">34133899</pub-id><pub-id pub-id-type="doi">10.1128/JVI.00402-21</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname><given-names>T</given-names></name><name><surname>Platt</surname><given-names>D</given-names></name><name><surname>Parida</surname><given-names>L</given-names></name></person-group><article-title>Variant analysis of SARS-CoV-2 genomes</article-title><source>Bull World Health Organ</source><year>2020</year><month>Jul</month><day>1</day><volume>98</volume><issue>7</issue><fpage>495</fpage><lpage>504</lpage><pub-id pub-id-type="pmcid">PMC7375210</pub-id><pub-id pub-id-type="pmid">32742035</pub-id><pub-id pub-id-type="doi">10.2471/BLT.20.253591</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>M</given-names></name><name><surname>Saha</surname><given-names>S</given-names></name></person-group><article-title>Structural insight into the role of novel SARS-CoV-2 E protein: A potential target for vaccine development and other therapeutic strategies</article-title><source>PLoS One</source><year>2020</year><volume>15</volume><issue>8</issue><elocation-id>e0237300</elocation-id><pub-id pub-id-type="pmcid">PMC7423102</pub-id><pub-id pub-id-type="pmid">32785274</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0237300</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guruprasad</surname><given-names>L</given-names></name></person-group><article-title>Human SARS COV -2 spike protein mutations</article-title><source>Proteins</source><year>2021</year><month>May</month><volume>89</volume><issue>5</issue><fpage>569</fpage><lpage>76</lpage><pub-id pub-id-type="pmcid">PMC8014176</pub-id><pub-id pub-id-type="pmid">33423311</pub-id><pub-id pub-id-type="doi">10.1002/prot.26042</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakur</surname><given-names>S</given-names></name><name><surname>Sasi</surname><given-names>S</given-names></name><name><surname>Pillai</surname><given-names>SG</given-names></name><name><surname>Nag</surname><given-names>A</given-names></name><name><surname>Shukla</surname><given-names>D</given-names></name><name><surname>Singhal</surname><given-names>R</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines</article-title><source>Front Med</source><year>2022</year><month>Feb</month><day>22</day><volume>9</volume><elocation-id>815389</elocation-id><pub-id pub-id-type="pmcid">PMC8902153</pub-id><pub-id pub-id-type="pmid">35273977</pub-id><pub-id pub-id-type="doi">10.3389/fmed.2022.815389</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>CB</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><name><surname>Choe</surname><given-names>H</given-names></name></person-group><article-title>Functional importance of the D614G mutation in the SARS-CoV-2 spike protein</article-title><source>Biochemical and Biophysical Research Communications</source><year>2021</year><month>Jan</month><volume>538</volume><fpage>108</fpage><lpage>15</lpage><pub-id pub-id-type="pmcid">PMC7664360</pub-id><pub-id pub-id-type="pmid">33220921</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.11.026</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>WT</given-names></name><name><surname>Carabelli</surname><given-names>AM</given-names></name><name><surname>Jackson</surname><given-names>B</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Thomson</surname><given-names>EC</given-names></name><name><surname>Harrison</surname><given-names>EM</given-names></name><etal/></person-group><article-title>SARS-CoV-2 variants, spike mutations and immune escape</article-title><source>Nat Rev Microbiol</source><year>2021</year><month>Jul</month><volume>19</volume><issue>7</issue><fpage>409</fpage><lpage>24</lpage><pub-id pub-id-type="pmcid">PMC8167834</pub-id><pub-id pub-id-type="pmid">34075212</pub-id><pub-id pub-id-type="doi">10.1038/s41579-021-00573-0</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Xing</surname><given-names>N</given-names></name><name><surname>Meng</surname><given-names>K</given-names></name><name><surname>Fu</surname><given-names>B</given-names></name><name><surname>Xue</surname><given-names>W</given-names></name><name><surname>Dong</surname><given-names>P</given-names></name><etal/></person-group><article-title>Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2</article-title><source>Cell Host &amp; Microbe</source><year>2021</year><month>Dec</month><volume>29</volume><issue>12</issue><fpage>1788</fpage><lpage>1801</lpage><elocation-id>e6</elocation-id><pub-id pub-id-type="pmcid">PMC8590493</pub-id><pub-id pub-id-type="pmid">34822776</pub-id><pub-id pub-id-type="doi">10.1016/j.chom.2021.11.005</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>BA</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Lokugamage</surname><given-names>KG</given-names></name><name><surname>Vu</surname><given-names>MN</given-names></name><name><surname>Bopp</surname><given-names>N</given-names></name><name><surname>Crocquet-Valdes</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis</article-title><source>Microbiology</source><year>2021</year><month>Oct</month><date-in-citation>cited 2022 May 3</date-in-citation><comment>Internet</comment><pub-id pub-id-type="doi">10.1101/2021.10.14.464390</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilmjärv</surname><given-names>S</given-names></name><name><surname>Abdul</surname><given-names>F</given-names></name><name><surname>Acosta-Gutiérrez</surname><given-names>S</given-names></name><name><surname>Estarellas</surname><given-names>C</given-names></name><name><surname>Galdadas</surname><given-names>I</given-names></name><name><surname>Casimir</surname><given-names>M</given-names></name><etal/></person-group><article-title>Concurrent mutations in RNA-dependent RNA polymerase and spike protein emerged as the epidemiologically most successful SARS-CoV-2 variant</article-title><source>Sci Rep</source><year>2021</year><month>Dec</month><volume>11</volume><issue>1</issue><fpage>13705</fpage><pub-id pub-id-type="pmcid">PMC8249556</pub-id><pub-id pub-id-type="pmid">34210996</pub-id><pub-id pub-id-type="doi">10.1038/s41598-021-91662-w</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eskier</surname><given-names>D</given-names></name><name><surname>Karakülah</surname><given-names>G</given-names></name><name><surname>Suner</surname><given-names>A</given-names></name><name><surname>Oktay</surname><given-names>Y</given-names></name></person-group><article-title>RdRp mutations are associated with SARS-CoV-2 genome evolution</article-title><source>PeerJ</source><year>2020</year><month>Jul</month><day>21</day><volume>8</volume><elocation-id>e9587</elocation-id><pub-id pub-id-type="pmcid">PMC7380272</pub-id><pub-id pub-id-type="pmid">32742818</pub-id><pub-id pub-id-type="doi">10.7717/peerj.9587</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pachetti</surname><given-names>M</given-names></name><name><surname>Marini</surname><given-names>B</given-names></name><name><surname>Benedetti</surname><given-names>F</given-names></name><name><surname>Giudici</surname><given-names>F</given-names></name><name><surname>Mauro</surname><given-names>E</given-names></name><name><surname>Storici</surname><given-names>P</given-names></name><etal/></person-group><article-title>Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant</article-title><source>J Transl Med</source><year>2020</year><month>Dec</month><volume>18</volume><issue>1</issue><fpage>179</fpage><pub-id pub-id-type="pmcid">PMC7174922</pub-id><pub-id pub-id-type="pmid">32321524</pub-id><pub-id pub-id-type="doi">10.1186/s12967-020-02344-6</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieva</surname><given-names>JL</given-names></name><name><surname>Madan</surname><given-names>V</given-names></name><name><surname>Carrasco</surname><given-names>L</given-names></name></person-group><article-title>Viroporins: structure and biological functions</article-title><source>Nat Rev Microbiol</source><year>2012</year><month>Jul</month><day>2</day><volume>10</volume><issue>8</issue><fpage>563</fpage><lpage>74</lpage><pub-id pub-id-type="pmcid">PMC7097105</pub-id><pub-id pub-id-type="pmid">22751485</pub-id><pub-id pub-id-type="doi">10.1038/nrmicro2820</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto-Torres</surname><given-names>J</given-names></name><name><surname>Verdiá-Báguena</surname><given-names>C</given-names></name><name><surname>Castaño-Rodriguez</surname><given-names>C</given-names></name><name><surname>Aguilella</surname><given-names>V</given-names></name><name><surname>Enjuanes</surname><given-names>L</given-names></name></person-group><article-title>Relevance of Viroporin Ion Channel Activity on Viral Replication and Pathogenesis</article-title><source>Viruses</source><year>2015</year><month>Jul</month><day>3</day><volume>7</volume><issue>7</issue><fpage>3552</fpage><lpage>73</lpage><pub-id pub-id-type="pmcid">PMC4517115</pub-id><pub-id pub-id-type="pmid">26151305</pub-id><pub-id pub-id-type="doi">10.3390/v7072786</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Liao</surname><given-names>CH</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Tan</surname><given-names>YJ</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway</article-title><source>Virus Research</source><year>2020</year><month>Sep</month><volume>286</volume><elocation-id>198074</elocation-id><pub-id pub-id-type="pmcid">PMC7309931</pub-id><pub-id pub-id-type="pmid">32589897</pub-id><pub-id pub-id-type="doi">10.1016/j.virusres.2020.198074</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandala</surname><given-names>VS</given-names></name><name><surname>McKay</surname><given-names>MJ</given-names></name><name><surname>Shcherbakov</surname><given-names>AA</given-names></name><name><surname>Dregni</surname><given-names>AJ</given-names></name><name><surname>Kolocouris</surname><given-names>A</given-names></name><name><surname>Hong</surname><given-names>M</given-names></name></person-group><article-title>Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers</article-title><source>Nat Struct Mol Biol</source><year>2020</year><month>Dec</month><volume>27</volume><issue>12</issue><fpage>1202</fpage><lpage>8</lpage><pub-id pub-id-type="pmcid">PMC7718435</pub-id><pub-id pub-id-type="pmid">33177698</pub-id><pub-id pub-id-type="doi">10.1038/s41594-020-00536-8</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariano</surname><given-names>G</given-names></name><name><surname>Farthing</surname><given-names>RJ</given-names></name><name><surname>Lale-Farjat</surname><given-names>SLM</given-names></name><name><surname>Bergeron</surname><given-names>JRC</given-names></name></person-group><article-title>Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be</article-title><source>Front Mol Biosci</source><year>2020</year><month>Dec</month><day>17</day><volume>7</volume><elocation-id>605236</elocation-id><pub-id pub-id-type="pmcid">PMC7773825</pub-id><pub-id pub-id-type="pmid">33392262</pub-id><pub-id pub-id-type="doi">10.3389/fmolb.2020.605236</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh Tomar</surname><given-names>PP</given-names></name><name><surname>Arkin</surname><given-names>IT</given-names></name></person-group><article-title>SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine</article-title><source>Biochemical and Biophysical Research Communications</source><year>2020</year><month>Sep</month><volume>530</volume><issue>1</issue><fpage>10</fpage><lpage>4</lpage><pub-id pub-id-type="pmcid">PMC7305885</pub-id><pub-id pub-id-type="pmid">32828269</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.05.206</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kern</surname><given-names>DM</given-names></name><name><surname>Sorum</surname><given-names>B</given-names></name><name><surname>Mali</surname><given-names>SS</given-names></name><name><surname>Hoel</surname><given-names>CM</given-names></name><name><surname>Sridharan</surname><given-names>S</given-names></name><name><surname>Remis</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs</article-title><source>Nat Struct Mol Biol</source><year>2021</year><month>Jul</month><volume>28</volume><issue>7</issue><fpage>573</fpage><lpage>82</lpage><pub-id pub-id-type="pmcid">PMC8772433</pub-id><pub-id pub-id-type="pmid">34158638</pub-id><pub-id pub-id-type="doi">10.1038/s41594-021-00619-0</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>P</given-names></name></person-group><article-title>SARS-CoV-2: pushing the E(nvelope)</article-title><source>J Physiol</source><year>2021</year><month>Jun</month><volume>599</volume><issue>11</issue><fpage>2785</fpage><lpage>6</lpage><pub-id pub-id-type="pmcid">PMC8250662</pub-id><pub-id pub-id-type="pmid">33873242</pub-id><pub-id pub-id-type="doi">10.1113/JP281601</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Cruz-cosme</surname><given-names>R</given-names></name><name><surname>Zhuang</surname><given-names>MW</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Teng</surname><given-names>S</given-names></name><etal/></person-group><article-title>A systemic and molecular study of subcellular localization of SARS-CoV-2 proteins</article-title><source>Sig Transduct Target Ther</source><year>2020</year><month>Dec</month><volume>5</volume><issue>1</issue><fpage>269</fpage><pub-id pub-id-type="pmcid">PMC7670843</pub-id><pub-id pub-id-type="pmid">33203855</pub-id><pub-id pub-id-type="doi">10.1038/s41392-020-00372-8</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation</article-title><source>Developmental Cell</source><year>2021</year><month>Feb</month><volume>56</volume><issue>4</issue><fpage>427</fpage><lpage>442</lpage><elocation-id>e5</elocation-id><pub-id pub-id-type="pmcid">PMC7832235</pub-id><pub-id pub-id-type="pmid">33422265</pub-id><pub-id pub-id-type="doi">10.1016/j.devcel.2020.12.010</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>Y</given-names></name><name><surname>Ng</surname><given-names>Y</given-names></name><name><surname>Tam</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name></person-group><article-title>Human Coronaviruses: A Review of Virus–Host Interactions</article-title><source>Diseases</source><year>2016</year><month>Jul</month><day>25</day><volume>4</volume><issue>4</issue><fpage>26</fpage><pub-id pub-id-type="pmcid">PMC5456285</pub-id><pub-id pub-id-type="pmid">28933406</pub-id><pub-id pub-id-type="doi">10.3390/diseases4030026</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabrera-Garcia</surname><given-names>D</given-names></name><name><surname>Bekdash</surname><given-names>R</given-names></name><name><surname>Abbott</surname><given-names>GW</given-names></name><name><surname>Yazawa</surname><given-names>M</given-names></name><name><surname>Harrison</surname><given-names>NL</given-names></name></person-group><article-title>The envelope protein of SARS-CoV-2 increases intra-Golgi pH and forms a cation channel that is regulated by pH</article-title><source>J Physiol</source><year>2021</year><month>Jun</month><volume>599</volume><issue>11</issue><fpage>2851</fpage><lpage>68</lpage><pub-id pub-id-type="pmcid">PMC8251088</pub-id><pub-id pub-id-type="pmid">33709461</pub-id><pub-id pub-id-type="doi">10.1113/JP281037</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>E</given-names></name><name><surname>Beitler</surname><given-names>JR</given-names></name><name><surname>Brochard</surname><given-names>L</given-names></name><name><surname>Calfee</surname><given-names>CS</given-names></name><name><surname>Ferguson</surname><given-names>ND</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><etal/></person-group><article-title>COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?</article-title><source>The Lancet Respiratory Medicine</source><year>2020</year><month>Aug</month><volume>8</volume><issue>8</issue><fpage>816</fpage><lpage>21</lpage><pub-id pub-id-type="pmcid">PMC7338016</pub-id><pub-id pub-id-type="pmid">32645311</pub-id><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30304-0</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsura</surname><given-names>H</given-names></name><name><surname>Sontake</surname><given-names>V</given-names></name><name><surname>Tata</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Edwards</surname><given-names>CE</given-names></name><name><surname>Heaton</surname><given-names>BE</given-names></name><etal/></person-group><article-title>Human Lung Stem Cell-Based Alveolospheres Provide Insights into SARS-CoV-2-Mediated Interferon Responses and Pneumocyte Dysfunction</article-title><source>Cell Stem Cell</source><year>2020</year><month>Dec</month><volume>27</volume><issue>6</issue><fpage>890</fpage><lpage>904</lpage><elocation-id>e8</elocation-id><pub-id pub-id-type="pmcid">PMC7577733</pub-id><pub-id pub-id-type="pmid">33128895</pub-id><pub-id pub-id-type="doi">10.1016/j.stem.2020.10.005</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>F</given-names></name><name><surname>Föller</surname><given-names>M</given-names></name></person-group><article-title>Regulation of ion channels and transporters by AMP-activated kinase (AMPK)</article-title><source>Channels</source><year>2014</year><month>Jan</month><volume>8</volume><issue>1</issue><fpage>20</fpage><lpage>8</lpage><pub-id pub-id-type="pmcid">PMC4048339</pub-id><pub-id pub-id-type="pmid">24366036</pub-id><pub-id pub-id-type="doi">10.4161/chan.27423</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>ME</given-names></name><name><surname>Carrasco</surname><given-names>L</given-names></name></person-group><article-title>Viroporins</article-title><source>FEBS Letters</source><year>2003</year><month>Sep</month><day>18</day><volume>552</volume><issue>1</issue><fpage>28</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">12972148</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClenaghan</surname><given-names>C</given-names></name><name><surname>Hanson</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Nichols</surname><given-names>CG</given-names></name></person-group><article-title>Coronavirus Proteins as Ion Channels: Current and Potential Research</article-title><source>Front Immunol</source><year>2020</year><month>Oct</month><day>9</day><volume>11</volume><elocation-id>573339</elocation-id><pub-id pub-id-type="pmcid">PMC7586316</pub-id><pub-id pub-id-type="pmid">33154751</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.573339</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahbar</surname><given-names>MR</given-names></name><name><surname>Jahangiri</surname><given-names>A</given-names></name><name><surname>Khalili</surname><given-names>S</given-names></name><name><surname>Zarei</surname><given-names>M</given-names></name><name><surname>Mehrabani-Zeinabad</surname><given-names>K</given-names></name><name><surname>Khalesi</surname><given-names>B</given-names></name><etal/></person-group><article-title>Hotspots for mutations in the SARS-CoV-2 spike glycoprotein: a correspondence analysis</article-title><source>Sci Rep</source><year>2021</year><month>Dec</month><volume>11</volume><issue>1</issue><elocation-id>23622</elocation-id><pub-id pub-id-type="pmcid">PMC8654821</pub-id><pub-id pub-id-type="pmid">34880279</pub-id><pub-id pub-id-type="doi">10.1038/s41598-021-01655-y</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrörs</surname><given-names>B</given-names></name><name><surname>Riesgo-Ferreiro</surname><given-names>P</given-names></name><name><surname>Sorn</surname><given-names>P</given-names></name><name><surname>Gudimella</surname><given-names>R</given-names></name><name><surname>Bukur</surname><given-names>T</given-names></name><name><surname>Rösler</surname><given-names>T</given-names></name><etal/></person-group><article-title>Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates</article-title><source>PLoS ONE</source><person-group person-group-type="editor"><name><surname>Khudyakov</surname><given-names>YE</given-names></name></person-group><year>2021</year><month>Sep</month><day>27</day><volume>16</volume><issue>9</issue><elocation-id>e0249254</elocation-id><pub-id pub-id-type="pmcid">PMC8475993</pub-id><pub-id pub-id-type="pmid">34570776</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0249254</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manzoor</surname><given-names>R</given-names></name><name><surname>Igarashi</surname><given-names>M</given-names></name><name><surname>Takada</surname><given-names>A</given-names></name></person-group><article-title>Influenza A Virus M2 Protein: Roles from Ingress to Egress</article-title><source>IJMS</source><year>2017</year><month>Dec</month><day>7</day><volume>18</volume><issue>12</issue><fpage>2649</fpage><pub-id pub-id-type="pmcid">PMC5751251</pub-id><pub-id pub-id-type="pmid">29215568</pub-id><pub-id pub-id-type="doi">10.3390/ijms18122649</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>S</given-names></name></person-group><article-title>Death by viroporin</article-title><source>Nat Rev Microbiol</source><year>2007</year><month>Dec</month><volume>5</volume><issue>12</issue><fpage>907</fpage></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamzami</surname><given-names>N</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>The mitochondrion in apoptosis: how Pandora’s box opens</article-title><source>Nat Rev Mol Cell Biol</source><year>2001</year><month>Jan</month><volume>2</volume><issue>1</issue><fpage>67</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">11413468</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farag</surname><given-names>NS</given-names></name><name><surname>Breitinger</surname><given-names>U</given-names></name><name><surname>El-Azizi</surname><given-names>M</given-names></name><name><surname>Breitinger</surname><given-names>HG</given-names></name></person-group><article-title>The p7 viroporin of the hepatitis C virus contributes to liver inflammation by stimulating production of Interleukin-1β</article-title><source>Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease</source><year>2017</year><volume>1863</volume><issue>3</issue><fpage>712</fpage><lpage>20</lpage><comment>Mar</comment><pub-id pub-id-type="pmid">27979709</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>IY</given-names></name><name><surname>Moriyama</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>MF</given-names></name><name><surname>Ichinohe</surname><given-names>T</given-names></name></person-group><article-title>Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome</article-title><source>Front Microbiol</source><year>2019</year><month>Jan</month><day>29</day><volume>10</volume><fpage>50</fpage><pub-id pub-id-type="pmcid">PMC6361828</pub-id><pub-id pub-id-type="pmid">30761102</pub-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.00050</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartoszewski</surname><given-names>R</given-names></name><name><surname>Matalon</surname><given-names>S</given-names></name><name><surname>Collawn</surname><given-names>JF</given-names></name></person-group><article-title>Ion channels of the lung and their role in disease pathogenesis</article-title><source>American Journal of Physiology-Lung Cellular and Molecular Physiology</source><year>2017</year><month>Nov</month><day>1</day><volume>313</volume><issue>5</issue><fpage>L859</fpage><lpage>72</lpage><pub-id pub-id-type="pmcid">PMC5792182</pub-id><pub-id pub-id-type="pmid">29025712</pub-id><pub-id pub-id-type="doi">10.1152/ajplung.00285.2017</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name></person-group><article-title>Acute respiratory failure in COVID-19: is it “typical” ARDS?</article-title><source>Crit Care</source><year>2020</year><month>Dec</month><volume>24</volume><issue>1</issue><fpage>198</fpage><pub-id pub-id-type="pmcid">PMC7202792</pub-id><pub-id pub-id-type="pmid">32375845</pub-id><pub-id pub-id-type="doi">10.1186/s13054-020-02911-9</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres Acosta</surname><given-names>MA</given-names></name><name><surname>Singer</surname><given-names>BD</given-names></name></person-group><article-title>Pathogenesis of COVID-19-induced ARDS: implications for an ageing population</article-title><source>Eur Respir J</source><year>2020</year><month>Sep</month><volume>56</volume><issue>3</issue><elocation-id>2002049</elocation-id><pub-id pub-id-type="pmcid">PMC7397945</pub-id><pub-id pub-id-type="pmid">32747391</pub-id><pub-id pub-id-type="doi">10.1183/13993003.02049-2020</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahbazi</surname><given-names>M</given-names></name><name><surname>Amri</surname><given-names>Maleh P</given-names></name><name><surname>Bagherzadeh</surname><given-names>M</given-names></name><name><surname>Moulana</surname><given-names>Z</given-names></name><name><surname>Sepidarkish</surname><given-names>M</given-names></name><name><surname>Rezanejad</surname><given-names>M</given-names></name><etal/></person-group><article-title>Linkage of Lambda Interferons in Protection Against Severe COVID-19</article-title><source>Journal of Interferon &amp; Cytokine Research</source><year>2021</year><month>Apr</month><day>1</day><volume>41</volume><issue>4</issue><fpage>149</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">33885337</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hariharan</surname><given-names>A</given-names></name><name><surname>Hakeem</surname><given-names>AR</given-names></name><name><surname>Radhakrishnan</surname><given-names>S</given-names></name><name><surname>Reddy</surname><given-names>MS</given-names></name><name><surname>Rela</surname><given-names>M</given-names></name></person-group><article-title>The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients</article-title><source>Inflammopharmacol</source><year>2021</year><month>Feb</month><volume>29</volume><issue>1</issue><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="pmcid">PMC7648206</pub-id><pub-id pub-id-type="pmid">33159646</pub-id><pub-id pub-id-type="doi">10.1007/s10787-020-00773-9</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilfong</surname><given-names>EM</given-names></name><name><surname>Croze</surname><given-names>R</given-names></name><name><surname>Fang</surname><given-names>X</given-names></name><name><surname>Schwede</surname><given-names>M</given-names></name><name><surname>Niemi</surname><given-names>E</given-names></name><name><surname>López</surname><given-names>GY</given-names></name><etal/></person-group><person-group person-group-type="editor"><name><surname>Zhao</surname><given-names>YY</given-names></name></person-group><article-title>Proinflammatory cytokines and ARDS pulmonary edema fluid induce CD40 on human mesenchymal stromal cells—A potential mechanism for immune modulation</article-title><source>PLoS ONE</source><year>2020</year><month>Oct</month><day>6</day><volume>15</volume><issue>10</issue><elocation-id>e0240319</elocation-id><pub-id pub-id-type="pmcid">PMC7537876</pub-id><pub-id pub-id-type="pmid">33021986</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0240319</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Notz</surname><given-names>Q</given-names></name><name><surname>Schmalzing</surname><given-names>M</given-names></name><name><surname>Wedekink</surname><given-names>F</given-names></name><name><surname>Schlesinger</surname><given-names>T</given-names></name><name><surname>Gernert</surname><given-names>M</given-names></name><name><surname>Herrmann</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome—An Observational Pilot Study</article-title><source>Front Immunol</source><year>2020</year><month>Oct</month><day>6</day><volume>11</volume><elocation-id>581338</elocation-id><pub-id pub-id-type="pmcid">PMC7573122</pub-id><pub-id pub-id-type="pmid">33123167</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.581338</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costela-Ruiz</surname><given-names>VJ</given-names></name><name><surname>Illescas-Montes</surname><given-names>R</given-names></name><name><surname>Puerta-Puerta</surname><given-names>JM</given-names></name><name><surname>Ruiz</surname><given-names>C</given-names></name><name><surname>Melguizo-Rodríguez</surname><given-names>L</given-names></name></person-group><article-title>SARS-CoV-2 infection: The role of cytokines in COVID-19 disease</article-title><source>Cytokine &amp; Growth Factor Reviews</source><year>2020</year><month>Aug</month><volume>54</volume><fpage>62</fpage><lpage>75</lpage><pub-id pub-id-type="pmcid">PMC7265853</pub-id><pub-id pub-id-type="pmid">32513566</pub-id><pub-id pub-id-type="doi">10.1016/j.cytogfr.2020.06.001</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name></person-group><article-title>Regulatory T Cells and Acute Lung Injury: Cytokines, Uncontrolled Inflammation, and Therapeutic Implications</article-title><source>Front Immunol</source><year>2018</year><month>Jul</month><day>9</day><volume>9</volume><fpage>1545</fpage><pub-id pub-id-type="pmcid">PMC6046379</pub-id><pub-id pub-id-type="pmid">30038616</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.01545</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanzawa</surname><given-names>N</given-names></name><name><surname>Nishigaki</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>Y</given-names></name><name><surname>Furukawa</surname><given-names>S</given-names></name><name><surname>Niiro</surname><given-names>A</given-names></name><etal/></person-group><article-title>Augmentation of chemokine production by severe acute respiratory syndrome coronavirus 3a/X1 and 7a/X4 proteins through NF-κB activation</article-title><source>FEBS Letters</source><year>2006</year><month>Dec</month><day>22</day><volume>580</volume><issue>30</issue><fpage>6807</fpage><lpage>12</lpage><pub-id pub-id-type="pmcid">PMC7094718</pub-id><pub-id pub-id-type="pmid">17141229</pub-id><pub-id pub-id-type="doi">10.1016/j.febslet.2006.11.046</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeDiego</surname><given-names>ML</given-names></name><name><surname>Nieto-Torres</surname><given-names>JL</given-names></name><name><surname>Regla-Nava</surname><given-names>JA</given-names></name><name><surname>Jimenez-Guardeño</surname><given-names>JM</given-names></name><name><surname>Fernandez-Delgado</surname><given-names>R</given-names></name><name><surname>Fett</surname><given-names>C</given-names></name><etal/></person-group><article-title>Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival</article-title><source>J Virol</source><year>2014</year><month>Jan</month><volume>88</volume><issue>2</issue><fpage>913</fpage><lpage>24</lpage><pub-id pub-id-type="pmcid">PMC3911641</pub-id><pub-id pub-id-type="pmid">24198408</pub-id><pub-id pub-id-type="doi">10.1128/JVI.02576-13</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>N</given-names></name><name><surname>Jeltema</surname><given-names>D</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group><article-title>The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation</article-title><source>IJMS</source><year>2019</year><month>Jul</month><day>6</day><volume>20</volume><issue>13</issue><fpage>3328</fpage><pub-id pub-id-type="pmcid">PMC6651423</pub-id><pub-id pub-id-type="pmid">31284572</pub-id><pub-id pub-id-type="doi">10.3390/ijms20133328</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>MN</given-names></name><name><surname>Rasmussen</surname><given-names>HB</given-names></name></person-group><article-title>AMPK: A regulator of ion channels</article-title><source>Communicative &amp; Integrative Biology</source><year>2012</year><month>Sep</month><volume>5</volume><issue>5</issue><fpage>480</fpage><lpage>4</lpage><pub-id pub-id-type="pmcid">PMC3502212</pub-id><pub-id pub-id-type="pmid">23181165</pub-id><pub-id pub-id-type="doi">10.4161/cib.21200</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrese</surname><given-names>V</given-names></name><name><surname>Stott</surname><given-names>JB</given-names></name><name><surname>Figueiredo</surname><given-names>HB</given-names></name><name><surname>Aubdool</surname><given-names>AA</given-names></name><name><surname>Hobbs</surname><given-names>AJ</given-names></name><name><surname>Jepps</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Angiotensin II Promotes K <sub>V</sub> 7.4 Channels Degradation Through Reduced Interaction With HSP90 (Heat Shock Protein 90)</article-title><source>Hypertension</source><year>2018</year><month>Jun</month><volume>71</volume><issue>6</issue><fpage>1091</fpage><lpage>100</lpage><pub-id pub-id-type="pmcid">PMC6390948</pub-id><pub-id pub-id-type="pmid">29686000</pub-id><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.118.11116</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>T</given-names></name><name><surname>Ockinger</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Byles</surname><given-names>V</given-names></name><name><surname>McColl</surname><given-names>A</given-names></name><name><surname>Hofer</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Critical role for calcium mobilization in activation of the NLRP3 inflammasome</article-title><source>Proceedings of the National Academy of Sciences</source><year>2012</year><month>Jul</month><day>10</day><volume>109</volume><issue>28</issue><fpage>11282</fpage><lpage>7</lpage><pub-id pub-id-type="pmcid">PMC3396518</pub-id><pub-id pub-id-type="pmid">22733741</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1117765109</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sievers</surname><given-names>F</given-names></name><name><surname>Wilm</surname><given-names>A</given-names></name><name><surname>Dineen</surname><given-names>D</given-names></name><name><surname>Gibson</surname><given-names>TJ</given-names></name><name><surname>Karplus</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega</article-title><source>Mol Syst Biol</source><year>2011</year><month>Oct</month><day>11</day><volume>7</volume><fpage>539</fpage><pub-id pub-id-type="pmcid">PMC3261699</pub-id><pub-id pub-id-type="pmid">21988835</pub-id><pub-id pub-id-type="doi">10.1038/msb.2011.75</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surya</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Torres</surname><given-names>J</given-names></name></person-group><article-title>Structural model of the SARS coronavirus E channel in LMPG micelles</article-title><source>Biochim Biophys Acta Biomembr</source><year>2018</year><month>Jun</month><volume>1860</volume><issue>6</issue><fpage>1309</fpage><lpage>17</lpage><pub-id pub-id-type="pmcid">PMC7094280</pub-id><pub-id pub-id-type="pmid">29474890</pub-id><pub-id pub-id-type="doi">10.1016/j.bbamem.2018.02.017</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Baxevanis</surname><given-names>AD</given-names></name></person-group><source>Current protocols in bioinformatics</source><year>2004</year><publisher-name>John Wiley and Sons</publisher-name><publisher-loc>New York</publisher-loc><date-in-citation>cited 2021 Sep 26</date-in-citation><comment>Internet</comment><pub-id pub-id-type="doi">10.1002/0471250953</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waterhouse</surname><given-names>A</given-names></name><name><surname>Bertoni</surname><given-names>M</given-names></name><name><surname>Bienert</surname><given-names>S</given-names></name><name><surname>Studer</surname><given-names>G</given-names></name><name><surname>Tauriello</surname><given-names>G</given-names></name><name><surname>Gumienny</surname><given-names>R</given-names></name><etal/></person-group><article-title>SWISS-MODEL: homology modelling of protein structures and complexes</article-title><source>Nucleic Acids Res</source><year>2018</year><day>02</day><volume>46</volume><issue>W1</issue><fpage>W296</fpage><lpage>303</lpage><pub-id pub-id-type="pmcid">PMC6030848</pub-id><pub-id pub-id-type="pmid">29788355</pub-id><pub-id pub-id-type="doi">10.1093/nar/gky427</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Heo</surname><given-names>L</given-names></name><name><surname>Seok</surname><given-names>C</given-names></name></person-group><article-title>GalaxyWEB server for protein structure prediction and refinement</article-title><source>Nucleic Acids Res</source><year>2012</year><month>Jul</month><volume>40</volume><issue>Web Server issue</issue><fpage>W294</fpage><lpage>297</lpage><pub-id pub-id-type="pmcid">PMC3394311</pub-id><pub-id pub-id-type="pmid">22649060</pub-id><pub-id pub-id-type="doi">10.1093/nar/gks493</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>IW</given-names></name><name><surname>Leaver-Fay</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Block</surname><given-names>JN</given-names></name><name><surname>Kapral</surname><given-names>GJ</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>MolProbity: all-atom contacts and structure validation for proteins and nucleic acids</article-title><source>Nucleic Acids Res</source><year>2007</year><month>Jul</month><volume>35</volume><issue>Web Server issue</issue><fpage>W375</fpage><lpage>383</lpage><pub-id pub-id-type="pmcid">PMC1933162</pub-id><pub-id pub-id-type="pmid">17452350</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkm216</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>CJ</given-names></name><name><surname>Headd</surname><given-names>JJ</given-names></name><name><surname>Moriarty</surname><given-names>NW</given-names></name><name><surname>Prisant</surname><given-names>MG</given-names></name><name><surname>Videau</surname><given-names>LL</given-names></name><name><surname>Deis</surname><given-names>LN</given-names></name><etal/></person-group><article-title>MolProbity: More and better reference data for improved all-atom structure validation</article-title><source>Protein Sci</source><year>2018</year><volume>27</volume><issue>1</issue><fpage>293</fpage><lpage>315</lpage><pub-id pub-id-type="pmcid">PMC5734394</pub-id><pub-id pub-id-type="pmid">29067766</pub-id><pub-id pub-id-type="doi">10.1002/pro.3330</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Im</surname><given-names>W</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Yuan</surname><given-names>A</given-names></name></person-group><article-title>Automated Builder and Database of Protein/Membrane Complexes for Molecular Dynamics Simulations</article-title><source>PLoS ONE</source><year>2007</year><month>Sep</month><day>12</day><volume>2</volume><issue>9</issue><elocation-id>e880</elocation-id><pub-id pub-id-type="pmcid">PMC1963319</pub-id><pub-id pub-id-type="pmid">17849009</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0000880</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>EL</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Jo</surname><given-names>S</given-names></name><name><surname>Rui</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>KC</given-names></name><name><surname>Dávila-Contreras</surname><given-names>EM</given-names></name><etal/></person-group><article-title>CHARMM-GUI Membrane Builder toward realistic biological membrane simulations</article-title><source>J Comput Chem</source><year>2014</year><month>Oct</month><day>15</day><volume>35</volume><issue>27</issue><fpage>1997</fpage><lpage>2004</lpage><pub-id pub-id-type="pmcid">PMC4165794</pub-id><pub-id pub-id-type="pmid">25130509</pub-id><pub-id pub-id-type="doi">10.1002/jcc.23702</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>WL</given-names></name><name><surname>Chandrasekhar</surname><given-names>J</given-names></name><name><surname>Madura</surname><given-names>JD</given-names></name><name><surname>Impey</surname><given-names>RW</given-names></name><name><surname>Klein</surname><given-names>ML</given-names></name></person-group><article-title>Comparison of simple potential functions for simulating liquid water</article-title><source>The Journal of Chemical Physics</source><year>1983</year><month>Jul</month><day>15</day><volume>79</volume><issue>2</issue><fpage>926</fpage><lpage>35</lpage></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klauda</surname><given-names>JB</given-names></name><name><surname>Venable</surname><given-names>RM</given-names></name><name><surname>Freites</surname><given-names>JA</given-names></name><name><surname>O’Connor</surname><given-names>JW</given-names></name><name><surname>Tobias</surname><given-names>DJ</given-names></name><name><surname>Mondragon-Ramirez</surname><given-names>C</given-names></name><etal/></person-group><article-title>Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types</article-title><source>J Phys Chem B</source><year>2010</year><month>Jun</month><day>17</day><volume>114</volume><issue>23</issue><fpage>7830</fpage><lpage>43</lpage><pub-id pub-id-type="pmcid">PMC2922408</pub-id><pub-id pub-id-type="pmid">20496934</pub-id><pub-id pub-id-type="doi">10.1021/jp101759q</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>RB</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Shim</surname><given-names>J</given-names></name><name><surname>Lopes</surname><given-names>PEM</given-names></name><name><surname>Mittal</surname><given-names>J</given-names></name><name><surname>Feig</surname><given-names>M</given-names></name><etal/></person-group><article-title>Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ<sup>(1)</sup> and χ<sup>(2)</sup> dihedral angles</article-title><source>J Chem Theory Comput</source><year>2012</year><month>Sep</month><day>11</day><volume>8</volume><issue>9</issue><fpage>3257</fpage><lpage>73</lpage><pub-id pub-id-type="pmcid">PMC3549273</pub-id><pub-id pub-id-type="pmid">23341755</pub-id><pub-id pub-id-type="doi">10.1021/ct300400x</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>JC</given-names></name><name><surname>Braun</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Gumbart</surname><given-names>J</given-names></name><name><surname>Tajkhorshid</surname><given-names>E</given-names></name><name><surname>Villa</surname><given-names>E</given-names></name><etal/></person-group><article-title>Scalable molecular dynamics with NAMD</article-title><source>J Comput Chem</source><year>2005</year><month>Dec</month><volume>26</volume><issue>16</issue><fpage>1781</fpage><lpage>802</lpage><pub-id pub-id-type="pmcid">PMC2486339</pub-id><pub-id pub-id-type="pmid">16222654</pub-id><pub-id pub-id-type="doi">10.1002/jcc.20289</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>JR</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Nekouzadeh</surname><given-names>A</given-names></name><name><surname>Decker</surname><given-names>KF</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><etal/></person-group><article-title>A multiscale model linking ion-channel molecular dynamics and electrostatics to the cardiac action potential</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><month>Jul</month><day>7</day><volume>106</volume><issue>27</issue><fpage>11102</fpage><lpage>6</lpage><pub-id pub-id-type="pmcid">PMC2700153</pub-id><pub-id pub-id-type="pmid">19549851</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0904505106</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryckaert</surname><given-names>JP</given-names></name><name><surname>Ciccotti</surname><given-names>G</given-names></name><name><surname>Berendsen</surname><given-names>HJC</given-names></name></person-group><article-title>Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes</article-title><source>Journal of Computational Physics</source><year>1977</year><month>Mar</month><volume>23</volume><issue>3</issue><fpage>327</fpage><lpage>41</lpage></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feller</surname><given-names>SE</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Pastor</surname><given-names>RW</given-names></name><name><surname>Brooks</surname><given-names>BR</given-names></name></person-group><article-title>Constant pressure molecular dynamics simulation: The Langevin piston method</article-title><source>The Journal of Chemical Physics</source><year>1995</year><month>Sep</month><day>15</day><volume>103</volume><issue>11</issue><fpage>4613</fpage><lpage>21</lpage></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darden</surname><given-names>T</given-names></name><name><surname>York</surname><given-names>D</given-names></name><name><surname>Pedersen</surname><given-names>L</given-names></name></person-group><article-title>Particle mesh Ewald: An <italic>N</italic>·log(<italic>N</italic>) method for Ewald sums in large systems</article-title><source>The Journal of Chemical Physics</source><year>1993</year><month>Jun</month><day>15</day><volume>98</volume><issue>12</issue><fpage>10089</fpage><lpage>92</lpage></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>W</given-names></name><name><surname>Dalke</surname><given-names>A</given-names></name><name><surname>Schulten</surname><given-names>K</given-names></name></person-group><article-title>VMD: Visual molecular dynamics</article-title><source>Journal of Molecular Graphics</source><year>1996</year><month>Feb</month><volume>14</volume><issue>1</issue><fpage>33</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8744570</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Greenblatt</surname><given-names>DM</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><etal/></person-group><article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title><source>J Comput Chem</source><year>2004</year><month>Oct</month><volume>25</volume><issue>13</issue><fpage>1605</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol</source><year>2014</year><month>Dec</month><volume>15</volume><issue>12</issue><fpage>550</fpage><pub-id pub-id-type="pmcid">PMC4302049</pub-id><pub-id pub-id-type="pmid">25516281</pub-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Pache</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Khodabakhshi</surname><given-names>AH</given-names></name><name><surname>Tanaseichuk</surname><given-names>O</given-names></name><etal/></person-group><article-title>Metascape provides a biologist-oriented resource for the analysis of systems-level datasets</article-title><source>Nat Commun</source><year>2019</year><month>Apr</month><day>3</day><volume>10</volume><issue>1</issue><elocation-id>1523</elocation-id><pub-id pub-id-type="pmcid">PMC6447622</pub-id><pub-id pub-id-type="pmid">30944313</pub-id><pub-id pub-id-type="doi">10.1038/s41467-019-09234-6</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><p><list list-type="alpha-upper" id="L1"><list-item><p>Analytical pipeline for determining the consensus sequences for Orf3a and E protein for the SARS-CoV-2 variants. The pipeline describes the steps from extraction of protein sequences for each protein to the determination of the position specific residue frequency.</p></list-item><list-item><p>Tables showing the number of sequences excluded and included in the analysis using a median length threshold.</p></list-item><list-item><p>Heatmap showing the position-specific residue intravariant frequency of Orf3q protein for each SARS-CoV-2 variant used in the analysis. Heatmap scale: - 0.05 to 0.25.</p></list-item><list-item><p>A stacked bar plot showing the position-specific residue change frequency of Orf3q protein for each SARS-CoV-2 variant used in the analysis.</p></list-item><list-item><p>Heatmap showing the position-specific residue intravariant frequency of E protein for each SARS-CoV-2 variant used in the analysis. Heatmap scale: - 0.05 to 0.25.</p></list-item><list-item><p>A stacked bar plot showing the position-specific residue change frequency of E protein for each SARS-CoV-2 variant used in the analysis.</p></list-item></list></p></caption><graphic xlink:href="EMS135919-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p><list list-type="alpha-upper" id="L2"><list-item><p>Multiple sequence alignment of representative mutations containing consensus sequences across all variants (except Alpha) of Orf3a protein.</p></list-item><list-item><p>Reference structure: Cryo-EM structure of Orf3a protein dimer (PDB id: 7KJR).</p></list-item><list-item><p>Structural superposition of variant specific mutations of Orf3a in SARS-CoV-2 variants with the reference structure: (i) Beta- Q57H (ii) Beta- S171L (iii) AY lineage of Delta- P104S (iv) Omicron- L106F (v) Omicron - S165F</p></list-item><list-item><p>TM- score matrix of Orf3a protein across SARS-CoV-2 variants.</p></list-item></list></p></caption><graphic xlink:href="EMS135919-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p><list list-type="alpha-upper" id="L3"><list-item><p>Insertion and equilibration of truncated Orf3a (40-125) from SARS-CoV-2 in a membrane system mimicking the endosomal compartment of a generalized human cell. The membrane is not shown in the figure to ease the visualization of the molecular machine. The upper channel has been pointed out using a dotted circle.</p></list-item><list-item><p>Movement of water molecules through the upper channel at different time points (i) 0 ns (ii) 0.5 ns (iii) 1 ns (iv) 1.5 ns (v) 2 ns (<xref ref-type="supplementary-material" rid="SD1">Supplementary Movie 1</xref>)</p></list-item><list-item><p>Insertion and equilibration of truncated Orf3a (40-125) from SARS-CoV-2 in a membrane system mimicking the endosomal compartment of a generalized human cell. The membrane is not shown in the figure to ease the visualization of the molecular machine. The lower channel has been pointed out using a dotted circle.</p></list-item><list-item><p>Movement of water molecules through the inner subunit channel at different time points (i) 0 ns (ii) 0.5 ns (iii) 1 ns (iv) 1.5 ns (v) 2 ns (<xref ref-type="supplementary-material" rid="SD1">Supplementary Movie 1</xref>)</p></list-item><list-item><p>Line plot showing the dynamics in the number of hydrogen bonds in the protein-membrane system as a function of time steps for 5ns where each time step is 0.1 ns.</p></list-item><list-item><p>Line plot showing the RMSD of the protein-membrane complex and its change over a course of 5 ns where each time step is 0.1 ns.</p></list-item><list-item><p>Line plot showing the total energy (kcal/mol) of the system in 5 ns of simulation with each 5000 steps=1 ps.</p></list-item><list-item><p>Matrix representation showing the RMSF of individual residues of the protein over the time span of 5 ns where each time step is 0.1 ns.</p></list-item></list></p></caption><graphic xlink:href="EMS135919-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p><list list-type="alpha-upper" id="L4"><list-item><p>Insertion and equilibration of E protein (8-40) of SARS-CoV-2 in a membrane system mimicking the ERGIC of human cells. The membrane is not shown in the figure to ease the visualisation of the molecular machine.</p></list-item><list-item><p>Movement of water molecules through the central pentameric channel of the TM region of the E protein at different time points (i) 0 ns (ii) 0.5 ns (iii) 1 ns (iv) 1.1 ns (v) 1.2 ns (vi) 1.3 ns (vii) 1.4 ns (viii)1.5 ns (ix) 2 ns (<xref ref-type="supplementary-material" rid="SD1">Supplementary Movie 3</xref>)</p></list-item><list-item><p>Line plot showing the dynamics in the number of hydrogen bonds in the protein-membrane system as a function of time steps for 5ns where each time step is 0.1 ns.</p></list-item><list-item><p>Line plot showing the RMSD of the protein-membrane complex and its change over a course of 5 ns where each time step is 0.1 ns.</p></list-item><list-item><p>Line plot showing the total energy (kcal/mol) of the system in 5 ns of simulation with each 5000 steps=1 ps.</p></list-item><list-item><p>Matrix representation showing the RMSF of individual residues of the protein over the time span of 5 ns where each time step is 0.1 ns.</p></list-item></list></p></caption><graphic xlink:href="EMS135919-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><p><list list-type="alpha-upper" id="L5"><list-item><p>Principal component analysis (PCA) scatter plot representation of the variability in the dataset along the first two PC axes (PC1- 53% variability; PC2- 29% variability). Control and infected samples are orthogonal to each other.</p></list-item><list-item><p>MA plot (M-log ratio of fold change; A- mean of normalized counts) for differentially significant gene expression in Infected samples compared to Controls.</p></list-item><list-item><p>Volcano plot showing significantly upregulated genes (in orange), significantly downregulated genes (in blue) and non-significantly expressed genes (in black) between infected cells and controls.</p></list-item><list-item><p>Bar plot showing gene counts of PRKAA1 gene between infected cells and controls. Error bars indicate Standard deviation.</p></list-item><list-item><p>Example bar plots of differentially upregulated genes between infected cells and controls. The values plotted are gene counts with the error bars indicating standard deviation. Genes plotted: CD40, IFNL1, IFNL2, IFNL3, IL12A, IL33, IL6 and NFκB1.</p></list-item><list-item><p>Same as E, but for differentially downregulated genes. Genes plotted: HSP90AB1, HSP90AA1 and HSP90B1.</p></list-item><list-item><p>Distribution showing the percentage of genes significantly upregulated (p &lt; 0.01) and with LFC &gt;2. 88% of the genes were upregulated while 12% of the genes were downregulated.</p></list-item><list-item><p>Gene enrichment analysis and gene ontology network obtained from upregulated genes in infected samples vs controls showing enrichment for immune functions and its associated signalling pathways. Metascape was used for this analysis. Different colored dots indicate different genes encoding the same function.</p></list-item><list-item><p>Protein-protein interaction (PPI) enrichment analysis showing cellular functions determined by the upregulated genes in infected samples vs controls. Metascape was used for this analysis. Different colored dots indicate different genes encoding similar protein-protein interactions.</p></list-item></list></p></caption><graphic xlink:href="EMS135919-f005"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Lipid composition of different membrane components of intracellular compartments (endosome and ERGIC)</title></caption><table frame="box" rules="all"><tbody><tr><td align="left" valign="top"/><td align="center" valign="top"><bold>Orf3a</bold></td><td align="center" valign="top"><bold>E protein</bold></td></tr><tr><td align="center" valign="top">Lipids ⇓</td><td align="center" valign="top" colspan="2">Intracellular compartments ⇓</td></tr><tr><td align="left" valign="top"/><td align="center" valign="top"><bold>Endosome</bold></td><td align="center" valign="top"><bold>ERGIC</bold></td></tr><tr><td align="center" valign="top">POPC</td><td align="center" valign="top">120</td><td align="center" valign="top">94</td></tr><tr><td align="center" valign="top">POPE</td><td align="center" valign="top">44</td><td align="center" valign="top">42</td></tr><tr><td align="center" valign="top">PSM</td><td align="center" valign="top">60</td><td align="center" valign="top">Not present</td></tr><tr><td align="center" valign="top">Cholesterol</td><td align="center" valign="top">120</td><td align="center" valign="top">28</td></tr><tr><td align="center" valign="top">bGMP</td><td align="center" valign="top">28</td><td align="center" valign="top">Not present</td></tr></tbody></table></table-wrap></floats-group></article>